Instead of developing new antibiotics, Hamlet identifies the molecular basis of a patient's sickness and creates molecules to shut off that specific response. This makes the treatment effective against both resistant and sensitive bacteria, representing a paradigm shift in treating infectious diseases.
While a compelling public narrative, the natural origin from breast milk was not an "automatic" advantage with the high-tech pharma industry. Developing a synthetic peptide was a prerequisite for being taken seriously in partnering discussions, bridging the gap between a biological discovery and a scalable drug.
Unlike systems where universities own faculty inventions, Sweden grants IP ownership directly to scientists. This structure compelled Hamlet Biopharma's founders to build a company themselves to commercialize their discoveries, as university funding for drug development was unavailable. This policy acts as an entrepreneurial catalyst.
Instead of screening vast libraries of compounds against a target, Hamlet first uses genome-wide and proteomic analysis to understand the core molecular basis of a disease. Only after defining the problem do they search for molecules to inhibit that specific disease pathway, letting the experiment guide them to the solution.
Beyond inducing cell death, Hamlet Biopharma's Alpha-1H therapy has a distinct mechanism. It programs bladder tumors to release cells piece by piece with each injection, triggering detachment from the bladder wall. This "peeling" effect physically reduces tumor size in addition to its cytotoxic properties.